Pharmacology, clinical

Inclusion Criteria

- Healthy male white subjects
 - 18 to 45 years of age
 - BMI between 18 and 28 kg/m2
 - Subjects who are able to understand and follow instructions and who are able to participate in the study for the entire period

Exclusion Criteria

- Relevant deviation from the normal range in the clinical examination; in clinical chemistry, hematology, or urinalysis
 - Resting heart rate in the awake subject below 45 BPM or above 90 BPM
 - Systolic blood pressure below 100 mmHg or above 145 mmHg
 - Diastolic blood pressure above 95 mmHg
 - Relevant pathological changes in the ECG such as a second or third-degree AV block, prolongation of the QRS complex over 120 msec or of the QT / QTc-interval over 450 msec for males
 - History of genetic muscle or bone disease of any kind
 - Completely sedentary or extremely fit subjects
 - Fractures in the preceding 12 months
 - Psychiatric diseases
 - History of peptic ulcers or relevant gastro-esophageal reflux disease
 - Subjects with hypersensitivity to the investigational drug riociguat or ranitidine, or to inactive constituents
 - Regular daily consumption of more than half a liter of usual beer or the equivalent
quantity of approximately 20 g of alcohol in another form, more than 1 L of xanthine-containing beverages, recent smoking history
 - Use of medication within the 2 weeks preceding the study which could have
interfered with the investigational drug riociguat or ranitidine
 - Subjects with a medical disorder, condition or history of such that would have
impaired the subject's ability to participate or complete this study in the opinion of
the investigator or the sponsor